MSLN, HER2 and MUC16, Three Promising Targets of CAR Therapy for Ovarian Cancer
Ovarian cancer, as a common gynecological tumor, is currently recognized as the most lethal gynecological malignancy. Several preclinical experiments and clinical trials have confirmed that adoptive cell immunotherapy using typical CAR-engineered T cells for OC is a promising treatment approach with striking clinical efficacy. The most popular targets for CAR-T cell therapy of ovarian cancer include mesothelin, HER2 and MUC16.
ACROBiosystems has developed an extensive collection of MSLN, HER2 and MUC16 proteins to support CAR-T cell therapy in ovarian cancer. The high activity of these proteins has been verified by FACS and ELISA that are uniquely suitable for evaluation of CAR expression.
>>> Detection of Anti-MSLN CAR Expression
Cat. No. MSN-HF223
Product: FITC-Labeled Human Mesothelin (296-580), His Tag
293 cells were transfected with anti-MSLN-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HF223, 1 μg/mL) and FITC-labeled protein control. Non-transfected 293 cells and FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-MSLN-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HF223).
>>> FACS Analysis of Anti-HER2 CAR Expression
Cat. No. HE2-HF224
Product: FITC-Labeled Human Her2, His Tag
2e5 of Anti-Her2 CAR-293 were stained with 100 μL of 1 μg/mL of FITC-Labeled Human Her2, His Tag (Cat. No. HE2-HF224) and negative control protein respectively, FITC signal was used to evaluate the binding activity.
>>> Binding Activity Measured by ELISA with a Linear Range of 2-78 ng/mL
Cat. No. CA5-H82F4
Product: Biotinylated Human CA125, Fc,Avitag
More CAR-T related products